Protalex — Investor Presentation (January 2016)
23 slides from Protalex's investor presentation, Jan 11, 2016
Slide 1: January, 2016
January, 2016
Slide 2: Disclaimer
Protalex , Inc. Disclaimer This presentation highlights certain information about Protalex , Inc . On July 31 , 2015 , we filed a registration statement, which included a preliminary prospectus, with the U . S . Securities and Exchange Commission (the “SEC”), SEC File No . 333 - 206008 (the “Registr
Slide 3: Forward-Looking Statement
Protalex , Inc. Forward - Looking Statement Statements made in this presentation stating the Company ’ s beliefs, intentions, and expectations are forward - looking statements. The Company ’ s actual results could differ materially from those projected. Additional information is contained in the Com
Slide 4: Protalex, Inc. (Symbol: PRTX) overview
Protalex , Inc. Protalex, Inc. (Symbol: PRTX) ▪ ITP (~$1b) ▪ Rheumatoid Arthritis (>$18B) ▪ Other Autoimmune Diseases ($Bs) 4 ▪ Experienced Management ▪ Strong Scientific Advisors ▪ Low - burn Model ▪ Funded - to - date by majority shareholder ▪ Highly - purified natural biologic ▪ Clinical experien
Slide 5: Investment Thesis
Protalex , Inc. Protalex Investment Thesis PRTX - 100 is a novel immunomodulatory biological with potential to be a blockbuster drug in various autoimmune diseases ▪ ITP — an orphan disease ▪ Rheumatoid arthritis — the largest autoimmune market To date, 5 clinical studies conducted demonstrate t
Slide 6: Preclinical Studies
Protalex , Inc. Preclinical Studies of PRTX - 100 PRTX - 100 inhibits B - cell activation, the expression of CD40 on the surface of B - cells and monocytes, and CD120b and CD16 on monocytes PRTX - 100 reduces footpad swelling in the murine CIA model of arthritis PRTX - 100 is not immunosuppres
Slide 7: Inhibits Platelet Phagocytosis in vitro
Protalex , Inc. PRTX - 100 Inhibits Platelet Phagocytosis in vitro Human monocytes were isolated from human blood and human platelets were labeled with PerCP Platelets were opsonized with W632 (anti - MHC Class I) and mixed with monocytes that had been treated with PRTX - 100 for 48 hours Mono
Slide 8: Treatment of Thrombocytopenia in a Murine Model of Severe ITP
Protalex , Inc. PRTX - 100 Treatment of Thrombocytopenia in a Murine Model of Severe ITP Chow, et al. 2010 model — involves both cellular and humoral immunity SCID mice receive splenocytes from CD61 KO mice Mice treated on day 8 after thrombocytopenia is established PRTraises platelet counts
Slide 9: Address Unmet Needs in the ITP and RA Markets
PRTX - 100 Address Unmet Needs in the ITP and RA Markets o PRTX - 100 reduces immune - mediate platelet destruction; existing therapies do not o To date, PRTX - 100 is safe and tolerable in humans; other ITP and RA drugs carry FDA black box warnings o The side effects of incumbent RA biologicals are
Slide 10: Clinical Experience
PRTX - 100 Clinical Experience Rheumatoid Arthritis (RA) 2005 – IND filed for RA 2006 – Phase 1 study completed 2007 – Second Phase 1 using PRTX - 100 with improved production/CMC processes 2010 - 11 – Phase 1b RA Study (PRTX - 100 - 103) in South Africa; presented at ACR Annual Meeting in N
Slide 11: Clinical Development Plans
PRTX - 100 Clinical Development Plans 11 2012 2013 2014 2015 2016 2017 Immune Thrombocytopenia Explore Partnership Preclinical Protalex, Inc. Rheumatoid Arthritis Phase 1b So. Africa PRTX - 100 - 103 Phase 1b in USA PRTX - 100 - 104 Phase 2 EU Phase 1/2 US Phase 1/2 - 105 Continuation Study
Slide 12: Orphan Drug Designation in ITP
Protalex , Inc. Orphan Drug Designation in ITP June 2015, FDA’s Office or Orphan Drugs Development grants Orphan Drug Designation (ODD) to PRTX - 100 in ITP in US October 2015, European Medicines Agency grants ODD to PRTX - 100 for ITP in Europe ODD provides: ▪ Certain market exclusivity, even
Slide 13: ITP Study Overview
Protalex , Inc. PRTX - 100 - 202/ - 203 : ITP Study Overview Phase 1/2, Open - Label, Single Arm Dose Ranging Study Patient Population: • Adult patients with persistent/chronic immune thrombocytopenia (ITP ) despite adequate therapy • Failed at least 1 prior ITP treatment • Platelet count < 30,0
Slide 14: Adult ITP patients refractory to TPO-RAs (US study)
Protalex , Inc. PRTX - 100 - 202: Adult ITP patients refractory to TPO - RAs 14 PRTX - 100 1 µg/kg PRTX - 100 3 µg /kg PRTX - 100 6 µg PRTX - 100 12 µ/kg PRTX - 100 18 µg/kg Dosing: IV infusion weekly for 4 weeks Primary objective: • Platelet response Secondary objectives: • Time to response • Quali
Slide 15: Adult ITP patients who have received one prior treatment (Europe study)
Protalex , Inc. PRTX - 100 - 203: Adult ITP patients who have received one prior treatment 15 Screening ≤ 21 days PRTX - 100 3 µg /kg PRTX - 100 6 µg PRTX - 100 12 µ/kg PRTX - 100 18 µg/kg Dosing: IV infusion weekly for 4 weeks Primary objective: • Safety Secondary objectives: • Platelet response •
Slide 16: Overall safety in RA
Protalex , Inc. PRTX - 100 - 104: Overall safety in RA Doses of 1.5 to 12 µg/kg PRTX - 100 appeared well - tolerated and demonstrated no dose - limiting toxicities in RA patients No treatment - related SAEs and no requirement for expedited reports to FDA Most commonly reported AEs were fatigue
Slide 17: Increases ACR50 Response in RA Patients on Background MTX Therapy
PRTX - 100 Increases ACR50 Response in RA Patients on Background MTX Therapy ACR50 Response Rate 0 5 10 15 20 25 30 35 0 29 57 85 PRTX - 100 + MTX Trial PRTX - 100 - 104: 41 patients w active RA randomized 3:1 Baseline MTX vs MTX + PRTX - 100, five weekly i.v . doses, 1.5, 3, 6, or 12 mcg/kg L
Slide 18: Continuation Study
Protalex , Inc. PRTX - 100 - 105 Continuation Study Enrollment commenced February, 2015 ; last dose/visit expected in 1Q16 Open - label, multiple fixed dose open to - 104 RA Study patients who indicated a desire for additional treatment Eleven former participants enrolled over a 6 - month peri
Slide 19: Patents and Intellectual Property
Protalex , Inc. Patents and Intellectual Property Patents (five issued in US and one in Japan, one EU intention to grant) ▪ Initial US patent 7,211,258, “Protein A compositions and methods of use” filed 2002 and issued 2007 for RA, juvenile RA, and systemic lupus erythematosus ▪ Continuation paten
Slide 20: Key Team Members
Protalex , Inc. Protalex Key Team Members Arnold P Kling – President, Director; Principal of Niobe Ventures, LLC, experienced investor in and manager of early stage technology companies James W Dowe III – Vice - Chair of SAB; active investor in biotechnology, computer software and investment man
Slide 21: Milestones
Protalex , Inc. Protalex Milestones x 4Q14 Filing IMPD and IND for PRTX - 100 in ITP in Europe & US x 1Q15 Initiation of PRTX - 100 - 105 continuation study x 2Q15 Complete PRTX - 100 - 104 study (US Phase 1B in RA) x 2Q15 Orphan Drug Designation for PRTX - 100 in ITP in US x 3Q15 Submit end of stud
Slide 22: Investment Thesis Summary
Protalex , Inc. Protalex Investment Thesis Summary PRTX - 100 – potentially a blockbuster drug ▪ Multiple clinical indications in both orphan and large markets (ITP, RA) ▪ Potentially applicable across a broad set of autoimmune diseases ▪ Considerable cost - of - goods advantage over competitors ▪
Slide 23: Thank you
Thank you 23